Skip to content
Screener

Free cash flow at other companies

Eli Lilly logo
Eli LillyLLY
$7.76B+458%
Pfizer logo
PfizerPFE
$2.18B+23.0%
Arrowhead Research logo
Arrowhead ResearchARWR
$81.88M-82.0%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$104.13M+153%
ALN
Alnylam PharmaceuticalsALNY
$292.04M+109%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$98M+12.5%

Other financials

Income statement

See full
Revenue$267.9M-40.7%
Gross profit$265.2M-40.8%
Operating income-$102.3M-173%
Net income-$114.6M-193%
EPS (diluted)-$0.69-199%

Balance sheet

See full
Cash & equivalents$350.1M+17.7%
Total debt$262.5M-67.0%
Total equity$439.7M-30.4%
Total assets$3.0B+0.3%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$16.1M+30.7%

Valuation

See full
Market cap$9.01B+38.9%
Enterprise value$8.92B+27.7%
P/S10.3×+3.4×

Profitability

See full
Gross margin98.2%-0.7pp
Operating margin-68%-234pp
Net margin-64.7%-299pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-105.5%+336pp
Debt / equity0.6×-0.7×
Current ratio7.9×+5.0×

Where this comes from

Calculated from Ionis Pharmaceuticals’s reported figures.

The source filing: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026. Open the filing →

Filed
Apr 29, 2026, 2:33 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000874015-26-000177

FAQ

What is Ionis Pharmaceuticals's free cash flow?
Ionis Pharmaceuticals (IONS) reported free cash flow of -$814.58M in Q1 2026.
How has Ionis Pharmaceuticals's free cash flow changed year-over-year?
Ionis Pharmaceuticals's free cash flow decreased by 398.7% year-over-year, from -$163.35M to -$814.58M.
What is the long-term trend for Ionis Pharmaceuticals's free cash flow?
Over 3 years (2021 to 2024), Ionis Pharmaceuticals's free cash flow has grown at a 207.2% compound annual growth rate (CAGR), from $18.84M to -$546.23M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.

Ask your AI about Ionis Pharmaceuticals's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude